Iron out KRAS-driven cancer

How to specifically target oncogenic KRAS-driven cancers while sparing normal tissues remains an unmet need in cancer therapy. In this issue of JEM, Jiang et al. (2022. J. Exp. Med. https://doi.org/10.1084/jem.20210739) leveraged KRAS-induced iron addiction in cancer cells to design a clever drug de...

Descripción completa

Detalles Bibliográficos
Autores principales: Lei, Guang, Gan, Boyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2022
Materias:
Insights
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919642/
https://www.ncbi.nlm.nih.gov/pubmed/35262627
http://dx.doi.org/10.1084/jem.20212166
_version_ 1784668974907129856
author Lei, Guang
Gan, Boyi
author_facet Lei, Guang
Gan, Boyi
author_sort Lei, Guang
collection PubMed
description How to specifically target oncogenic KRAS-driven cancers while sparing normal tissues remains an unmet need in cancer therapy. In this issue of JEM, Jiang et al. (2022. J. Exp. Med. https://doi.org/10.1084/jem.20210739) leveraged KRAS-induced iron addiction in cancer cells to design a clever drug delivery approach to enable selective inhibition of KRAS signaling in mutant KRAS tumors but not in normal tissues, offering a new strategy for treating this largely incurable disease.
format Online
Article
Text
id pubmed-8919642
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-89196422022-10-04 Iron out KRAS-driven cancer Lei, Guang Gan, Boyi J Exp Med Insights How to specifically target oncogenic KRAS-driven cancers while sparing normal tissues remains an unmet need in cancer therapy. In this issue of JEM, Jiang et al. (2022. J. Exp. Med. https://doi.org/10.1084/jem.20210739) leveraged KRAS-induced iron addiction in cancer cells to design a clever drug delivery approach to enable selective inhibition of KRAS signaling in mutant KRAS tumors but not in normal tissues, offering a new strategy for treating this largely incurable disease. Rockefeller University Press 2022-03-09 /pmc/articles/PMC8919642/ /pubmed/35262627 http://dx.doi.org/10.1084/jem.20212166 Text en © 2022 Lei and Gan https://creativecommons.org/licenses/by-nc-sa/4.0/http://www.rupress.org/terms/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Insights
Lei, Guang
Gan, Boyi
Iron out KRAS-driven cancer
title Iron out KRAS-driven cancer
title_full Iron out KRAS-driven cancer
title_fullStr Iron out KRAS-driven cancer
title_full_unstemmed Iron out KRAS-driven cancer
title_short Iron out KRAS-driven cancer
title_sort iron out kras-driven cancer
topic Insights
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919642/
https://www.ncbi.nlm.nih.gov/pubmed/35262627
http://dx.doi.org/10.1084/jem.20212166
work_keys_str_mv AT leiguang ironoutkrasdrivencancer
AT ganboyi ironoutkrasdrivencancer

Ejemplares similares